Skip to main content

The c-ret receptor tyrosine kinase as a target for drug discovery

Objective


The aim of this project is to generate a comprehensive platform of intellectual property to facilitate the discovery and development of a new generation of therapeutics with the ability to activate or inhibit the c-Ret receptor tyrosine kinase. Mutations in c-Ret are directly implicated in human cancers, and the c-Ret ligand, GDNF, is being developed as a therapeutic agent for neurodegenerative disorders such as Parkinson's disease and ALS. To develop c-Ret as a target for drug discovery we propose: i) to validate c-Ret as a drug target; ii) to develop scaleable assays for high throughput screening of c-Ret inhibitors and activators; iii) to isolate artificial c-Ret peptide ligands; iv) to determine the 3D structures of the extracellular and kinase domains of wild type and oncogenic c-Ret; v) to identify ligand binding sites in the c-Ret extracellular domain. Our long-term goal is to enter into license agreements with interested user groups for the exploitation of the generated knowledge and technology platform.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

KAROLINSKA INSTITUTE
Address
Retzius Vaeg 8
171 77 Stockholm
Sweden

Participants (3)

AUGUST KIRCHENSTEIN INSTITUTE OF MICROBIOLOGY AND VIROLOGY
Latvia
Address
Ratsupites 1
1067 Riga
CANCER RESEARCH UK
United Kingdom
Address
Lincoln's Inn Field 61
WC2A 3PX London
XERION PHARMACEUTICALS GMBH
Germany
Address
Fraunhoferstrasse 9
82152 Planegg / Krailling